Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study
Rare Kidney Diseases Proving Difficult For Both Companies
Executive Summary
Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.